Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Alzamend Neuro

Alzamend Neuro Issues Letter to Stockholders
From Alzamend Neuro
Via Business Wire
Tickers ALZN
Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement
From Alzamend Neuro
Via Business Wire
Tickers ALZN
Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients
From Alzamend Neuro
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001
From Alzamend Neuro
Via Business Wire
Tickers ALZN
Alzamend Neuro CEO Stephan Jackman to Participate on the “Mental Health, More Critical Than Ever” Panel at the Maxim Group’s Virtual Healthcare Conference
From Alzamend Neuro
Via Business Wire
Tickers ALZN
Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s
From Alzamend Neuro
Via Business Wire
Tickers ALZN
Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today
From Alzamend Neuro
Via Business Wire
Tickers ALZN
Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer’s Disease
From Alzamend Neuro
Via Business Wire
Tickers ALZN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS